What You Should Know:
– Personalis, Inc. (NASDAQ: PSNL) today announced agreements with long-time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy.
– The company has received a $50M investment from…
Continue Reading
OpenAI and Moderna announced the pair have expanded their partnership to offer the pharma giant’s employees access to ChatGPT Enterprise, a platform that allows customizable GPTs to be developed for a specific purpose. Through ChatGPT…
Continue Reading
By Shania Kennedy April 25, 2023 – Moderna and IBM announced a partnership to leverage novel technologies, such as artificial intelligence (AI) and quantum computing, to accelerate messenger RNA (mRNA) research.
Quantum computing is a subset…
Epstein-Barr is among the most common viruses, but no vaccines are available to prevent its infection. Merck is joining the pursuit for a vaccine by striking a deal with Opko Health, paying $50 million…
Continue Reading
Moderna’s ambitions in messenger RNA technology include therapies that do their editing work inside the patient. To that end, the biotech company is starting an R&D collaboration with a division of ElevateBio that brings…
Continue Reading
A Moderna messenger RNA vaccine for influenza now has preliminary data from a pivotal study showing the shot prompted a strong immune response to the more common strains of the virus but fell short against less common strains.
The results reported Thursday are from one of two pivotal studies for the Moderna vaccine, mRNA-1010, which is assessing the shot for safety and immune response. A separate Phase 3 study is evaluating the shot for efficacy. Results from that study could come as early as next month. Moderna’s vaccine encodes hemagglutinin, a protein on the surface of the influenza virus that is also…
